Group items tagged

About 1 in 8 U.S. women (just under 12%) will develop invasive breast cancer over the course of her lifetime.

In 2013, an estimated 232,340 new cases of invasive breast cancer were expected to be diagnosed in women in the U.S.,

About 2,240 new cases of invasive breast cancer were expected to be diagnosed in men in 2013. A man’s lifetime risk of breast cancer is about 1 in 1,000.

Imaging tests, such as ultrasound or CT scans, of your abdomen and pelvis. These tests can help determine the size, shape and structure of your ovaries. Blood test, which can detect a protein (CA 125) found on the surface of ovarian cancer cells. Surgery to remove a tissue sample and abdominal fluid to confirm a diagnosis of ovarian cancer. Minimally invasive or robotic surgery may be an option. If cancer is discovered, the surgeon may immediately begin surgery to remove as much of the cancer as possible.

Stages of ovarian cancer include: Stage I. Cancer is found in one or both ovaries. Stage II. Cancer has spread to other parts of the pelvis. Stage III. Cancer has spread to the abdomen. Stage IV. Cancer is found outside the abdomen.

Cervical cancer is cancer arising from the cervix.[1] It is due to the abnormal growth of cells that have the ability to invade or spread to other parts of the body.[2] Early on there are typically no symptoms. Later symptoms may include: abnormal vaginal bleeding, pelvic pain or pain during sex.[1]

Cervical cancer typically develops from precancerous changes over 10 to 20 years

HPV vaccines protect against two high risk strains of this family of viruses and may prevent up to 65 to 75% of cervical cancers

About 5% to 10% of breast cancers are thought to be hereditary, caused by abnormal genes passed from parent to child.

Women who are diagnosed with breast cancer and have an abnormal BRCA1 or BRCA2 gene often have a family history of breast cancer, ovarian cancer, and other cancers. Still, most people who develop breast cancer did not inherit an abnormal breast cancer gene and have no family history of the disease

Abnormal BRCA1 and BRCA2 genes may account for up to 10% of all breast cancers, or 1 out of every 10 cases

MOST woman in Britain can probably name the signs of breast cancer. But how many of us could identify just one symptom of an even more deadly disease, ovarian cancer?

In fact, the shocking answer is only three per cent - which may explain why we have one of the worst survival rates in Europe.

Three quarters of women are only diagnosed once the cancer has spread, so it's not surprising that, out of the 7,000 new cases every year, only a third of women will live for five years.

For pancreatic cancer: For all stages combined, the 1-year relative survival rate is 25%, and the 5-year survival is estimated as less than 5% [81] to 6%.[7] For local disease, the 5-year survival is approximately 20%.[7][8] For locally advanced and for metastatic disease, which collectively represent over 80%[8] to 85-90%[19] of individuals, the median survival is about 10 and 6 months, respectively.[57] Without active treatment, metastatic pancreatic cancer has a median survival of 3–5 months;[19] complete remission is very rare.

Prognosis

une 23, 2008 -- A symptoms checklist, combined with a blood test, can catch 80% of ovarian cancer in its earliest, most curable stages, a new study suggests.

"The symptom index and the CA125 test each finds 50% to 60% of women with early disease," Andersen tells WebMD. "But when they're combined, if either one is positive, we might be able to identify 80.6% of women with early stage ovarian cancer. Women with early stage disease have good chance of a cure -- it's just that right now, we don't find many of them in time.

The symptoms that warn of ovarian cancer aren't, in themselves, very specific. They may seem to be gastrointestinal or psychological rather than gynecological in nature.

While Angelina Jolie's announcement that she had a preventive double mastectomy raised awareness of breast cancer, it did not lead to more people understanding how gene mutations actually affect breast cancer risk.

researchers noted that the risk of developing breast cancer is between 5 and 15 percent for women without the BRCA mutation.

Dr. Karen Lu, MD Anderson Cancer Center, on fighting ovarian cancer and the blood test that may tell about a woman’s risk of developing ovarian cancer.

Beginning in February, large nonhuman subjects have received weekly injections of cancer cells into their livers, creating a consistent model in a "controlled environment." This month, the subjects will undergo MRIs to determine whether they now have liver cancer. If affirmative, the Kanzius noninvasive radio-wave cancer treatment will be administered, allowing data to be collected and analyzed. The success of these tests is mandatory to move forward in approaching the U.S. Food and Drug Administration and ultimately advancing to human trials.

Signs and Symptoms of Ovarian Cancer Bloating Pelvic or abdominal pain Difficulty eating or feeling full quickly Urinary symptoms (urgency or frequency)

Epithelial ovarian cancer is the fifth most common cause of cancer in women worldwide bearing the highest mortality rate among all gynaecological cancers.

This kid went through over 4,000 proteins before finding mesothelin, a pancreatic, ovarian and lung cancer biomarker and developed a quick and cheap test for it's detection. Credit to Dr. Anirban Maitra, Professor of Pathology, Oncology, and Chemical and Biomolecular Engineering at Johns Hopkins School of Medicine, for recognizing the enthusiasm of this kid.

Most ovarian cysts are functional in nature and harmless (benign).[1][2] Ovarian cysts affect women of all ages. They occur most often, however, during a woman's childbearing years. Some ovarian cysts cause problems, such as bleeding and pain. Surgery may be required to remove cysts larger than 5 centimeters in diameter.

Functional cysts form as a normal part of the menstrual cycle. Such cysts may include: Follicular cyst, the most common type of ovarian cyst. In menstruation, a follicle containing the ovum (unfertilized egg) will rupture during ovulation. If this does not occur, a follicular cyst of more than 2.5 cm diameter may result.[3] Corpus luteum cysts appear after ovulation. The corpus luteum is the remnant of the follicle after the ovum has moved to the fallopian tubes. This normally degrades within 5–9 days. A corpus lutem that is more than 3 cm is defined as cystic.[3] Thecal cysts occur within the thecal layer of cells surrounding developing oocytes. Under the influence of excessive hCG, thecal cells may proliferate and become cystic. This is usually on both ovaries.[3]

Non-functional cysts may include: An ovary with many cysts, which may be found in normal women, or within the setting of polycystic ovary syndrome. Cysts caused by endometriosis, known as chocolate cysts. Hemorrhagic ovarian cyst Dermoid cyst Ovarian serous cystadenoma Ovarian mucinous cystadenoma Paraovarian cyst Cystic adenofibroma Borderline tumoral cysts

1 in 8 Women, will be diagnosed with breast cancer in their lifetime

All diseases have proteins, or concentrations of proteins, specifically linked to them called biomarkers, and identifying these can prove a powerful diagnostic tool. Antibodies can be used to test for specific biomarkers because they only bind to specific molecules or groups of molecules. Problems can arise when they bind to groups of similar molecules, leading to false positives and unreliable information.

Some of us share a genetic mutation that could kill us.

At just 25, Elise was confronted with a choice that is hard to imagine: live with the constant fear of cancer or have a preventative double mastectomy to remove both her breasts.

While viewers enjoy watching episodes of their favorite TV shows back-to-back, advertisers suffer because video-on-demand (VOD) providers do not want to alienate their viewers by running advertisements.

Critics say that the company’s reliance on subscriptions alone poses a problem, because an increase in price will translate into lost subscribers.

This loyal customer base can also be used to leverage the findings of a study by Annalect, – Omnicom Media Group’s marketing technology platform – which suggests that binge viewers don’t actually mind ads.